Serum IL-23 levels reflect a myeloid inflammatory signature and predict the response to apremilast in patients with psoriatic arthritis
An enhanced myeloid inflammatory signature characterizes PsA monocyte-derived macrophages, and serum IL-23 levels represent candidate biomarkers for PsA response to apremilast.
Authors
- Francesca Motta (ORCID: https://orcid.org/0000-0002-8093-2734)
- Carlo Selmi (ORCID: https://orcid.org/0000-0002-0323-0376)
- Natasa Isailovic (ORCID: https://orcid.org/0000-0002-9819-8822)
- Daniela Renna
- Giacomo Maria Guidelli (ORCID: https://orcid.org/0000-0003-2645-3182)
- Angela Ceribelli (ORCID: https://orcid.org/0000-0001-5116-4724)
- Antonio Tonutti (ORCID: https://orcid.org/0009-0000-9534-6853)
- Marta Caprioli (ORCID: https://orcid.org/0000-0002-1151-4125)
- Maria De Santis (ORCID: https://orcid.org/0000-0002-3196-1336)
- Nicoletta Luciano (ORCID: https://orcid.org/0000-0002-1822-7882)
- Rita Ragusa
- Radu Marian Rivara
Institutions
- Humanitas University (IT)
- IRCCS Humanitas Research Hospital (IT)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2024-12-04
- DOI
- https://doi.org/10.3389/fimmu.2024.1455134
- Citations
- 3
- Primary Topic
- Psoriasis: Treatment and Pathogenesis
- Type
- article
- Field-Weighted Citation Impact
- 0.72
Funders
- Amgen